STOK on Nasdaq

Stoke Therapeutics, Inc.

American pharmaceutical preparations company based in Bedford.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Maravai LifeSciences Holdings, Inc., LifeVantage or Kamada Ltd., or pick any stock.

TickerSTOK on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersBedford, United States
Incorporated inDE²
Business address45 Wiggins Avenue, Bedford, Ma 01730²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-11.2%Operating margin³

-3.7%Net margin³

404.5%Revenue growth, 2025³

-2.0%Return on equity³

$44.9MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentSelling, general and admin

Research and development67¢$137.9M
Selling, general and admin33¢$67.1M
Interest0¢$9.0K

Out of $184.4M in revenue.³ The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

Kept or used elsewhere

Capital spending1¢$670.0K
Kept or used elsewhere99¢$44.9M

Out of $45.6M of cash from operations.³

Financial statements

Revenue⁴⁵³$184.4M in 2025+1387% since 2022

Operating income⁶⁷⁸⁴⁵³-$20.6M in 2025−42% since 2019

Net income⁶⁷⁸⁴⁵³-$6.9M in 2025−79% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Revenue	$184.4M	$36.6M
Research and development	$137.9M	$89.1M
Sales, general and administrative	$67.1M	$48.8M
Total operating expenses	$205.0M	$137.9M
Loss from operations	-$20.6M	-$101.4M
Interest income (expense), net	$13.8M	$12.6M
Other income (expense), net	-$51.0K	-$247.0K
Total other income (expense)	$13.7M	$12.4M
Net loss	-$6.9M	-$89.0M
Net loss per share, basic	-$0.12	-$1.65
Net loss per share, diluted	-$0.12	-$1.65
Weighted-average common shares outstanding, basic	59.2M shares	54.0M shares
Weighted-average common shares outstanding, diluted	59.2M shares	54.0M shares
Unrealized gain (loss) on marketable securities	$694.0K	-$127.0K
Total other comprehensive gain (loss)	$694.0K	-$127.0K
Comprehensive loss	-$6.2M	-$89.1M

Total assets⁶⁷⁸⁴⁵³$418.4M in 2025+83% since 2019

Total liabilities⁶⁷⁸⁴⁵³$66.0M in 2025+1427% since 2019

Shareholders’ equity⁷⁸⁴⁵³$352.5M in 2025+57% since 2019

Cash⁶⁷⁸⁴⁵³$84.2M in 2025−62% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.³

Period ending	2025-12-31	2025-07-31	2024-12-31	2023-12-31
Cash and cash equivalents	$84.2M		$128.0M
Marketable securities - short term	$200.4M		$88.9M
Accounts receivable	$5.9M		$1.7M
Prepaid expenses	$8.7M		$11.1M
Other current assets	$3.9M		$2.3M
Restricted cash - short term	$494.0K		$75.0K
Interest receivable	$2.0M		$700.0K
Total current assets	$305.7M		$232.8M
Restricted cash - long term	$227.0K		$721.0K
Operating lease right-of-use assets	$3.1M	$1.8M	$4.3M
Marketable securities - long term	$106.3M		$29.8M
Property and equipment, net	$3.1M		$3.9M
Total assets	$418.4M		$271.6M
Accounts payable	$4.9M		$2.5M
Accrued and other current liabilities	$41.0M		$18.6M
Deferred revenue - current portion	$11.9M		$19.0M
Total current liabilities	$57.9M		$40.1M
Deferred revenue - net of current portion	$7.0M
Other long term liabilities	$1.1M		$2.5M
Total long term liabilities	$8.1M		$2.5M
Total liabilities	$66.0M		$42.5M
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 58,921,999 and 54,032,826 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$5.0K		$5.0K
Additional paid-in capital	$849.6M		$720.0M
Accumulated other comprehensive income (loss)	$543.0K		-$151.0K
Accumulated deficit	-$497.7M		-$490.8M
Total stockholders equity	$352.5M		$229.0M	$159.6M
Total liabilities and stockholders equity	$418.4M		$271.6M
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	300.0M shares		300.0M shares
Common stock, shares issued	58.9M shares		54.0M shares
Common stock, shares outstanding	58.9M shares		54.0M shares

Period ending	2025-12-31	2025-07-31	2024-12-31	2023-12-31
Cash and cash equivalents	$84.2M		$128.0M
Marketable securities - short term	$200.4M		$88.9M
Accounts receivable	$5.9M		$1.7M
Prepaid expenses	$8.7M		$11.1M
Other current assets	$3.9M		$2.3M
Restricted cash - short term	$494.0K		$75.0K
Interest receivable	$2.0M		$700.0K
Total current assets	$305.7M		$232.8M
Restricted cash - long term	$227.0K		$721.0K
Operating lease right-of-use assets	$3.1M	$1.8M	$4.3M
Marketable securities - long term	$106.3M		$29.8M
Property and equipment, net	$3.1M		$3.9M
Total assets	$418.4M		$271.6M
Accounts payable	$4.9M		$2.5M
Accrued and other current liabilities	$41.0M		$18.6M
Deferred revenue - current portion	$11.9M		$19.0M
Total current liabilities	$57.9M		$40.1M
Deferred revenue - net of current portion	$7.0M
Other long term liabilities	$1.1M		$2.5M
Total long term liabilities	$8.1M		$2.5M
Total liabilities	$66.0M		$42.5M
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 58,921,999 and 54,032,826 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$5.0K		$5.0K
Additional paid-in capital	$849.6M		$720.0M
Accumulated other comprehensive income (loss)	$543.0K		-$151.0K
Accumulated deficit	-$497.7M		-$490.8M
Total stockholders equity	$352.5M		$229.0M	$159.6M
Total liabilities and stockholders equity	$418.4M		$271.6M
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	300.0M shares		300.0M shares
Common stock, shares issued	58.9M shares		54.0M shares
Common stock, shares outstanding	58.9M shares		54.0M shares

Cash from operations⁶⁷⁸⁴⁵³$45.6M in 2025

Capital spending⁶⁷⁸⁴⁵³$670.0K in 2025−59% since 2019

Free cash flow⁶⁷⁸⁴⁵³$44.9M in 2025

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Net loss	-$6.9M	-$89.0M
Depreciation	$1.8M	$2.2M
Amortization and accretion of marketable securities	-$1.1M	-$1.6M
Stock-based compensation	$32.2M	$27.5M
Impairment of right of use asset	$696.0K
Loss on disposal of property and equipment	$145.0K
Reduction in the carrying amount of right of use assets	$2.4M	$2.3M
Accounts receivable	-$4.3M	-$50.0K
Prepaid expenses and other current assets	-$545.0K	-$1.8M
Accounts payable, accrued liabilities, and operating leases	$21.3M	$3.1M
Deferred revenue	-$130.0K	-$29.4M
Net cash provided by (used in) operating activities	$45.6M	-$86.9M
Purchases of property and equipment	-$670.0K	-$203.0K
Purchases of marketable securities	-$322.7M	-$167.3M
Sales of marketable securities	$136.6M	$60.0M
Net cash used in investing activities	-$186.8M	-$107.5M
Proceeds from issuance of common stock upon exercise of stock options	$8.6M	$1.7M
Proceeds from employee stock purchase plan	$1.0M	$532.0K
Proceeds from controlled equity offering sales agreement, net of commissions	$87.8M	$9.0M
Proceeds from follow-on offering, net of underwriting discounts, commissions and offering costs		$119.9M
Net cash provided by financing activities	$97.4M	$131.1M
Net decrease in cash, cash equivalents and restricted cash	-$43.8M	-$63.2M
Right-of-use assets recognized in exchange for operating leases	$1.8M
Property and equipment included in accrued expense and accounts payable	$482.0K	$61.0K

Compare Stoke Therapeutics, Inc. with another company

Leadership

Who has led Stoke Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Arthur Tzianabos2025–now

Chief financial officer

Chief operating officer

Huw M. Nash2019–2024

20202025

Chief executive officerIan F. Smith Mar 20, 2025 to now¹¹
Chief executive officerEdward M. Kaye Md. Jun 18, 2019 to Mar 18, 2025¹²
ChairArthur Tzianabos Mar 20, 2025 to now¹³
Chief financial officerThomas Leggett May 17, 2024 to now¹⁴
Chief financial officerStephen J. Tulipano Jun 18, 2019 to Jun 7, 2024¹⁵
Chief operating officerHuw M. Nash Jun 18, 2019 to Jun 7, 2024¹⁶

Board members and other officers (18)

Chief Scientific OfficerThomas McCauley Jul 17, 2026 to now¹⁷
Chief Patient OfficerJason Hoitt Jun 23, 2025 to now¹⁸
Chief Business OfficerHuw M. Nash Jul 3, 2024 to Jul 3, 2024¹⁹
Chief Medical OfficerBarry Ticho Jun 18, 2019 to now²⁰
EVP, Head of ResearchGene Liau Jun 18, 2019 to Mar 4, 2021²¹
Board memberClare Kahn Apr 7, 2026 to now²²
Board memberAlexander Cumbo Sep 25, 2026 to now²³
Board memberIan F. Smith Sep 20, 2023 to now²⁴
Board memberGarry E. Menzel Jan 27, 2021 to now²⁵
Board memberJulie Smith Jun 5, 2020 to now²⁶
Board memberAdrian R. Krainer Jun 18, 2019 to now²⁷
Board memberArthur A. Levin Jun 18, 2019 to now²⁸
Board memberArthur Tzianabos Jun 18, 2019 to now²⁹
Board memberEdward M. Kaye Md. Jun 18, 2019 to now¹²
Board memberSamuel W. Hall Jun 18, 2019 to Sep 12, 2019³⁰
Board memberSeth Loring Harrison Jun 18, 2019 to now³¹
Board memberJennifer Burstein Jun 19, 2019 to now³²
General counselRobin A. Walker Nov 18, 2019 to Jul 9, 2020³³

Former names

ASOthera Pharmaceuticals, Inc.Nov 24, 2014 to Nov 24, 2014²

Timeline

Mar 20, 2025New chief executive Ian F. Smith becomes CEO¹¹
Jun 18, 2019New chief executive Edward M. Kaye Md. becomes CEO¹²

Filings

438 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 202 insider forms, 56 large holders, 99 other. The latest 20:

Oct 2, 20264 EDGAR
Oct 2, 2026144 EDGAR
Oct 2, 20264 EDGAR
Sep 30, 2026SCHEDULE 13G EDGAR
Sep 25, 20264 EDGAR
Sep 25, 20263 EDGAR
Sep 25, 20268-K EDGAR
Sep 3, 20264 EDGAR
Aug 18, 20264 EDGAR
Aug 18, 20264 EDGAR
Aug 18, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 12, 2026SCHEDULE 13G/A EDGAR
Aug 6, 2026SCHEDULE 13G/A EDGAR
Aug 5, 20264 EDGAR
Aug 3, 2026144 EDGAR
Aug 3, 20268-K EDGAR
Aug 3, 2026424B5 EDGAR
Aug 3, 2026S-8 EDGAR
Aug 3, 202610-Q EDGAR

The 438 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 56 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
BlackRock, Inc.	5,877,357	$192.3M	0.0%	+491,643
Rtw Investments, LP	5,623,525	$184.0M	1.6%	No change
Fmr LLC	5,313,100	$173.8M	0.0%	−70,566
Lynx1 Capital Management LP	4,038,404	$132.1M	15.3%	−725,269
Redmile Group, LLC	3,945,920	$129.1M	8.7%	−218,200
Wellington Management Group Llp	3,519,301	$115.2M	0.0%	+423,601
Morgan Stanley	3,452,795	$113.0M	0.0%	+29,515
Baker Bros. Advisors LP	3,336,697	$109.2M	0.5%	No change
Toronto Dominion Bank	3,173,258	$103.8M	0.2%	No change
State Street Corp	2,852,240	$93.3M	0.0%	+575,728
Vanguard Capital Management LLC	2,586,937	$84.6M	0.0%	+231,334
Bvf Inc/il	2,547,557	$83.4M	2.1%	No change
Assenagon Asset Management S.A.	2,256,776	$73.8M	0.0%	+1,349,761
Siren, L.L.C.	1,995,347	$65.3M	1.3%	No change
Deerfield Management Company, L.P.	1,823,500	$59.7M	0.7%	No change
Jupiter Topco LLC	1,814,408	$59.4M	0.0%	New
Geode Capital Management, LLC	1,524,309	$49.9M	0.0%	+202,049
Dimensional Fund Advisors LP	1,013,911	$33.2M	0.0%	+23,975
Polar Capital Holdings Plc	833,716	$27.3M	0.1%	−298,795
EcoR1 Capital, LLC	735,000	$24.0M	1.2%	+635,000
Mpm Bioimpact LLC	723,314	$23.7M	1.4%	−43,724
Opaleye Management Inc.	700,000	$22.9M	2.1%	No change
Goldman Sachs Group Inc	575,344	$18.8M	0.0%	−255,358
Vanguard Portfolio Management LLC	566,993	$18.6M	0.0%	+104,311
Baillie Gifford & Co	517,275	$16.9M	0.0%	−57,907

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARStoke Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARStoke Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2025
4
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2022
5
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2023
6
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2019
7
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2020
8
SEC EDGARStoke Therapeutics, Inc. 10-K for fiscal 2021
9
SEC EDGARStoke Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGARStoke Therapeutics, Inc. 10-Q for fiscal 2026
11
SEC EDGARIan F. Smith, Chief executive officer
12
SEC EDGAREdward M. Kaye Md., Chief executive officer
13
SEC EDGARArthur Tzianabos, Chair
14
SEC EDGARThomas Leggett, Chief financial officer
15
SEC EDGARStephen J. Tulipano, Chief financial officer
16
SEC EDGARHuw M. Nash, Chief operating officer
17
SEC EDGARThomas McCauley, Chief Scientific Officer
18
SEC EDGARJason Hoitt, Chief Patient Officer
19
SEC EDGARHuw M. Nash, Chief Business Officer
20
SEC EDGARBarry Ticho, Chief Medical Officer
21
SEC EDGARGene Liau, EVP, Head of Research
22
SEC EDGARClare Kahn, Board member
23
SEC EDGARAlexander Cumbo, Board member
24
SEC EDGARIan F. Smith, Board member
25
SEC EDGARGarry E. Menzel, Board member
26
SEC EDGARJulie Smith, Board member
27
SEC EDGARAdrian R. Krainer, Board member
28
SEC EDGARArthur A. Levin, Board member
29
SEC EDGARArthur Tzianabos, Board member
30
SEC EDGARSamuel W. Hall, Board member
31
SEC EDGARSeth Loring Harrison, Board member
32
SEC EDGARJennifer Burstein, Board member
33
SEC EDGARRobin A. Walker, General counsel